BioAge Labs, Inc. (BIOA) is a pre-revenue clinical-stage biopharmaceutical company with no approved products. For the quarter ended March 31, 2026, total assets were $397.7M against total liabilities of $18.5M, yielding reported stockholders' equity of $379.1M. Under a liquidation lens, recoverable asset value is dominated by cash and marketable securities. Cash and cash equivalents were $241.8M (100% recovery), current marketable securities $141.4M, and noncurrent marketable securities $1.7M — together these liquid financial assets total approximately $384.9M and are recoverable at or near par subject only to mark-to-market adjustments. Accrued interest receivable of $1.9M recovers at ~90-95%. PP&E gross was $1.66M with $543K accumulated depreciation (net $1.1M); at a 50-60% haircut, recovery is approximately $0.6-0.7M. The ROU asset of $2.7M receives a 0% liquidation recovery per lens convention; the corresponding ASC 842 operating lease liability of $2.9M ($0.6M current, $2.3M noncurrent) remains at face value. Intangible assets and pipeline IP carry zero recovery. Total identifiable liquidation value approximates $388-389M gross assets recoverable versus $18.5M in liabilities at face, indicating a positive net recovery to equity of approximately $370M. This is broadly consistent with MFFAIS's latest CLV/LLV/OLV of approximately $224M, which likely applies a more conservative haircut to the marketable securities portfolio or reflects a liquidity discount. The primary drivers of recovery posture are: (1) a cash-heavy balance sheet funded by the September 2024 IPO ($207.3M net) and a January/February 2026 follow-on offering ($107.6M + $16.2M net), and (2) an absence of long-term debt (only a $500K note payable maturing within the remainder of fiscal year). Operating burn for Q1 2026 was approximately $24M per the cash flow statement, implying a runway well in excess of 12 months from current cash levels. The deferred revenue balance of $6.2M (current) reflects the Eli Lilly collaboration agreement recognized in 2025; this is a liability at face but partially offsets cash consumption going forward. Material off-balance-sheet contingency: the filing discloses that BIOA is party to a January 7, 2025 securities class action complaint; no accrual is reflected, and potential liability is unquantified. Lead program azelaprag was terminated in January 2025 due to liver transaminitis; BGE-102 is now the sole lead candidate in early development. Prior period comparison is to the annual 10-K for the year ended December 31, 2025, which showed $204.1M federal NOLs fully reserved with a 100% valuation allowance — these deferred tax assets carry zero liquidation value under the lens. Filing discusses pipeline contingent milestone and royalty obligations under license agreements in MD&A but does not separately tag these commitments in XBRL; they would not extinguish on wind-up and represent a contingent liability tail not captured in the balance sheet.
▼ Community Notes